5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. It was developed in the 1990s by a team led by David E. Nichols at Purdue University. 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans. Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.
Modality of use
5-IAI is generally sold via research chemicals suppliers as a powder and administered orally or via insufflation. There are no reports of injecting use of this substance. The most common dosage range is between 20-200 mg in a single session, however a re-dosing is also possible. Sometimes 5-IAI is taken together with other drugs of abuse, such as MDMA and others stimulants (to enhance the psychotropic effects), benzodiazepines, cannabis, alcohol (to reduce the side effects)
Although some aminoindans have been investigated for their important bronchodilating and analgesic effects, to date, there are no approved indications for 5-IAI use in humans.
Considering the absence of formal studies about the clinical effects of 5-IAI in humans, we explored the users reports present within the drugs forum in order to reconstruct the pattern of acute toxicity, desirable, and undesirable effects induced by this substance. 5-IAI is generally considered a less potent MDMA substitute producing pleasant stimulant effects. Desirable effects include: mild euphoria, sociability, increased self-confidence, increased desire to dance, increased intensity of the perceptions and colors, slight distortion of time and space. Users report a rapid onset of action even after ten minutes with a peak effect that lasts about one hour. The comedown is normally not so unpleasant, and it is similar to a standard hangover. In contrast, some users reported that effects are not satisfactory, and cannot compete with those exerted by MDMA. Furthermore, users also described negative effects of 5-IAI, such as: anxiety, psychomotor agitation, panic attacks, tachycardia, headache, insomnia, prolonged hallucinations, and derealization.